New York City, NY – According to filings with the U.S. Securities and Exchange Commission, TMRW Life Sciences is raising $105,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Joshua Abram played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TMRW Life Sciences
TMRW safeguards the worlds most precious cells for life. The TMRW platform revolutionizes the management, identification, and storage of fertility cells, replacing the manual and analog methods that have remained largely unchanged since IVF was first used in animal husbandry more than 50 years ago. Developed in partnership with leading fertility doctors and embryologists, TMRWs technology will play a central role in the births of tens of millions of people in the coming years by reducing the risk of loss or misidentification of the priceless cells used in IVF. Our automation eliminates error-prone manual tasks in the embryology lab, allowing embryologists to focus on the most skilled and technical aspects of their work. In 2021, TMRW ivfOS was recognized as one of Fast Companys World Changing Ideas in the Software Category. The TMRW team includes many of the worlds most celebrated pioneers in clinical medicine, reproductive biology, embryology, and cryogenic biobanking who have synthesized their collective knowledge, vision, and experience in the development of the TMRW platform. Weve brought together a diverse, cross-disciplinary team to achieve our mission and were always looking for more innovators to join us in creating a better tomorrow.

To learn more about TMRW Life Sciences, visit http://www.tmrw.org/

Contact:
Joshua Abram, Chief Executive Officer
866-733-8679
joshua@tmrw.org
https://www.linkedin.com/in/joshuaabram/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved